| 1 year of age | 248 |
| 11β-hydroxylase deficiency | 288 |
| 46,XX disorder of sex development | 109, 206 |
| 46,XX ovotesticular disorder of sex development | 308 |
| AAP | 125 |
| Abetalipoproteinemia | 223 |
| Abnormal external genitalia | 113 |
| Abnormal uterine bleeding | 1*suppl |
| Accelerator hypothesis | 281 |
| Adherence | 225 |
| Adiponectin | 180 |
| Adolescence | 17 |
| Adolescent | 1*suppl, 18*suppl, 28*suppl, 41*suppl, 46*suppl, 50*suppl, 233 |
| Adrenal hypoplasia | 206 |
| Adrenal insufficiency | 241 |
| Adult height | 71 |
| Alkaline phosphatase | 104 |
| Androgen-insensitivity syndrome | 50*suppl |
| Anti-Müllerian hormone | 79 |
| Application | 125 |
| Aromatase deficiency | 109 |
| Autoimmune thyroiditis | 303 |
| Bisphenol A | 86 |
| Body fat percentage | 168 |
| Body mass index | 281 |
| Calculator | 125 |
| Carney complex | 117 |
| Central hypothyroidism | 218, 223 |
| Central precocious puberty | 37 |
| Central puberty precocious | 117 |
| Childhood | 17, 241 |
| Children | 29, 86, 180, 281, 329 |
| Children and adolescents | 45 |
| Coagulopathy | 1*suppl |
| Combined pituitary hormone deficiency | 212, 261 |
| Congenital adrenal hyperplasia | 288 |
| Congenital hypothyroidism | 275, 303 |
| Contraception | 28*suppl |
| Contraceptive services | 28*suppl |
| Counselling | 28*suppl |
| CYP19A1 gene | 109 |
| Cyprus | 175 |
| D-lactate | 160 |
| Deficiency | 248 |
| Developmental disabilities | 41*suppl |
| Diabetes mellitus | 189, 315 |
| Diabetic ketoacidosis | 160, 189 |
| Diagnosis | 18*suppl |
| Double diabetes | 55 |
| Dysmenorrhea | 7*suppl |
| Education | 95 |
| eHealth | 225 |
| Endometriosis | 7*suppl |
| Epimutation | 1 |
| Euthyroid sick syndrome | 143, 223 |
| Family planning | 28*suppl |
| Final height | 295 |
| Functional | 18*suppl |
| Genotype | 1 |
| GLI2 mutations | 319 |
| Glycemic control | 233 |
| GnRH | 37 |
| GnRH analogue | 37 |
| Gonadotropin releasing hormone agonist | 37 |
| Graves’ disease | 197 |
| Growth | 225 |
| Growth chart | 125 |
| Growth disorders | 130 |
| Growth hormone | 225 |
| Growth hormone deficiency | 319 |
| Growth hormone treatment | 295 |
| Growth velocity | 71 |
| Guideline | 125 |
| Heavy menstrual bleeding | 1*suppl |
| Hormone replacement therapy | 46*suppl |
| Human growth hormone treatment | 71 |
| Hydroxymethylfurfural | 79 |
| Hypertension | 29, 125 |
| Hypogonadism | 46*suppl |
| Hypophosphatasia | 104 |
| Hypophosphatemic rickets | 151 |
| Hypopituitarism | 261 |
| Hypoprolactinemia | 218 |
| Hypothalamic amenorrhea | 18*suppl |
| IGF-I | 130 |
| IGFBP-3 | 130 |
| IGSF1 | 218 |
| Imprinting disorders | 1 |
| Incidence | 288 |
| Incidence rate | 175 |
| Increased intestinal permeability | 303 |
| Insulin | 189 |
| Insulin resistance | 180 |
| Internipple distance | 269 |
| Internipple index | 269 |
| Intramuscular ACTH | 241 |
| Iodine | 329 |
| Iodine deficiency | 256 |
| Irisin | 168 |
| Ischemia-modified albumin | 45 |
| Isolated growth hormone deficiency | 295 |
| Knowledge levels | 95 |
| Large cell calcifying Sertoli cell tumor | 117 |
| Leuprolide | 37 |
| Lipodystrophy | 17 |
| Liquid chromatography-mass spectrometry | 86 |
| Long acting reversible contraception | 28*suppl |
| Macular retinal thickness | 63 |
| Macular retinal volume | 63 |
| Male adolescent | 168 |
| Menstruation | 41*suppl |
| Metabolic syndrome | 55, 63, 180 |
| Metformin | 315 |
| Metreleptin | 17 |
| MIRAGE syndrome | 206 |
| Missense mutation | 212 |
| Mobile | 125 |
| Motivational interviewing | 225 |
| Multiple pituitary hormone deficiency | 295, 319 |
| Muscle mass | 168 |
| Mutation | 104 |
| Müllerian aplasia | 50*suppl |
| Myocarditis | 160, 202 |
| National Prophylaxis Program | 248 |
| Neonatal screening | 288 |
| Nesfatin-1 | 29 |
| Neurofibromatosis Noonan syndrome | 113 |
| Neurofibromatosis type-1 | 202 |
| Newborn | 104 |
| NF1 gene | 113 |
| Obesity | 29, 45, 180 |
| Optical coherence tomography | 63 |
| Oral contraceptive pills | 1*suppl |
| Orthorexic eating behavior | 233 |
| Osteochondromyxoma | 117 |
| Pediatric obesity | 63 |
| Pediatric or childhood chronic liver diseases | 143 |
| Pediatric transport | 189 |
| Pelvic pain | 7*suppl |
| Permanent | 275 |
| Phenotype | 1 |
| Pheochromocytoma | 202 |
| PHEX | 151 |
| Pituitary stalk interruption syndrome | 71, 212 |
| Pituitary transcription factors | 261 |
| Polydactyly | 319 |
| Precocious puberty | 37 |
| Pregnancy in adolescence/prevention and control | 28*suppl |
| Prehospital care | 189 |
| Prevalence | 55, 256 |
| Prevention | 315 |
| Progeria | 17 |
| Progeria syndrome | 315 |
| PROP1 gene | 261 |
| Puberal stage | 168 |
| Puberty | 37, 79, 295 |
| Questionnaire | 95 |
| Rat | 79 |
| Receptor Roundabout-1 gene | 212 |
| Reliability | 241 |
| Risk behaviors | 233 |
| School-age children | 256 |
| Second-tier | 288 |
| Short stature | 125, 130 |
| Six month L-thyroxine dose | 275 |
| Soluble CD40 ligand (sCD40L) | 197 |
| Soluble receptor for advanced glycation end-products | 160 |
| SOX9 | 308 |
| SRY-negative | 308 |
| Steroid profiling | 288 |
| Subclinical hypothyroidism | 143 |
| Thiol/disulfide homeostasis | 45 |
| Thyroid function test | 143 |
| Thyroid hormone | 197 |
| Thyroid volume | 197 |
| Transient | 275 |
| Treatment | 18*suppl, 151 |
| Turkey | 86, 256, 269, 329 |
| Turner syndrome | 95 |
| Type 1 diabetes | 55, 175, 233, 281 |
| Urinary iodine concentration | 329 |
| Urine | 86 |
| Vaginal opening | 79 |
| Vitamin D | 248 |
| Zonulin | 303 |